US Edition
News from cancernetwork.com
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top cancernetwork.com News
Cancer · Hong KongHONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The study will…See the Story
Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab
73% Center coverage: 30 sources
FDA · United States(MedPage Today) -- The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Approval was based on results...See the Story
AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment
80% Center coverage: 10 sources
FDA · United States(MedPage Today) -- Under a program designed to accelerate the approval of products that could address key national priorities, the FDA said it proactively awarded a national priority voucher to teclistamab (Tecvayli) in combination with daratumumab...See the Story
Myeloma Combination Cuts Line for FDA Approval After Strong ASH Results
71% Center coverage: 7 sources
